Hi, Does anyone know the sequencing error rates in Illumina platform?
-
-
The Illumina specificity for the v4 kit (75 PE) is of 1.33 % forward and almost 1.7 reverse, for a Qphred of 30 -
If my data is 75bp not strand, it means that it close to 1bp error per read?Originally posted by francois.sabot View PostComment
-
Yes, theoretically. But it seems to be better to consider it somehow a little higher (around 2% max). Do not forget that you may also have SNP/InDel between your ref and your data, thus explaining some 'errors' you might seeComment
-
That's true; Thanks~Comment
-
The are much more likely to occur at the 3' end of the read, and, a proportion of the reads have much more than one error, so lots of reads will be error free.Originally posted by sixguns View Post
HOWEVER I think the Illumina error rate may be misleading us. I believe they only count MAPPABLE reads to their PHIX74 CONTROL. Now, a read which has lots of errors will NOT MAP, hence will not count toward the error rate! Simply by tweaking their mappability thresholds, they can choose any error rate they want to match a reasonable yield...Comment
-
Yes but how can you calculate the 'true' errors rate, meaning the level of misreading, the level of chimeria, etc... For that you must know perfectly your DNA you are sequencing, and you cannot, due to continual modification of it... However, you can estimate it based on the common sequences between reference and tested sequences, and in calculating the false of non-SNP mismatches /indels.Comment
-
Francois, is there a paper/document describing in more details the suggestions you just gave above. I have DNA which we prepared by doing PCR on a normal individual,confirmed size by CE and also are planning to do Sanger sequencing.Comment
-
In fact those specs came from my classical provider (Integragen, France), from their own experience... No paper associated with so. Sorry :sOriginally posted by cdry7ue View PostComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment